Home | Health | Hypertension
InterCure, Ltd., today announced new study findings that demonstrate RESPeRATE, the FDA-cleared, CE marked hypertension treatment device, has been shown to effectively treat Asian and non-Asian patients with similar benefits. A second study showed that device-guided breathing may also have a beneficial effect on the steep increase of blood pressure (BP) that accompanies awakening from overnight sleep, known as "Morning Surge." Results of the findings will be presented as poster presentations at the International Society of Hypertension (ISH) Scientific Meeting in Fukouka, Japan, October 15-19, 2006. The 200 patient east-west analysis of published data compared the response of Asian and non-Asian patients to device-guided breathing. Asians and non-Asians both benefit from RESPeRATE treatment with remarkably similar responses. Among patients with uncontrolled blood pressure, the analysis reports a reduction of 13.7/8.4 mmHg and 13.2/7.5 mmHg for non-Asians and Asians, respectively, following eight weeks of daily device-guided breathing. No patients experienced adverse effects, and outcomes were not impacted by gender, body mass index, or medication status. Lead author Benjamin Gavish, PhD, Chief Scientist of InterCure in Israel, said, "Cultural differences suggest that people from the East are much more receptive to using breathing-based methods to affect health. It is very encouraging to find that both Asians and non-Asians respond in the same way to the use of RESPeRATE, effectively lowering their blood pressure. The device manifests the universality of the treatment that 'communicates' with our body on a very basic level." The second study to be presented at ISH demonstrates that device-guided breathing may have a beneficial effect on the Morning Surge in BP, the steep increase of blood pressure that accompanies awakening from overnight sleep. The results of this pilot study may reflect the known mediating effect of paced breathing on sympatho-vagal imbalance. This phenomenon is clinically significant, as it has been shown to be a predictor of clinical cerebrovascular disease in elderly hypertensives. According to the American Heart Association, more than 65 million Americans have high blood pressure, and despite wide availability of traditional treatment methods of medication, diet and exercise, only 34% of that population is able to reach its lower blood pressure goals. Hypertension is the number one cause of stroke and left untreated, high blood pressure may also lead to heart attack, kidney or heart failure and other life-threatening conditions. About RESPeRATE RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks. About InterCure, Ltd. InterCure, a medical device company, has become a leader in the growing Personal Therapeutic Device category. Its broadly patented "device-guided breathing" technology platform enables a systematic reduction in sympathetic outflow of the autonomous nervous system. InterCure is successfully selling the world's first hypertension treatment device, RESPeRATE(R). With multiple published clinical trials, regulatory approvals in most key markets (FDA over-the-counter ("OTC") clearance, CE mark, Korean FDA and others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (http://www.intercure.com, http://www.resperate.com)
Article Source: http://www.content.onlypunjab.com
InterCure, Ltdwww.intercure.com
Please Rate this Article
5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated
